Device Trial Radar · NCT01645696
Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics
Last checked: Nov 19, 2026Latest source record: Dec 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 2012
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Becton, Dickinson and CompanyPublic (BDX)
- Sponsor type
- Industry
- First posted
- Jul 20, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Device feasibility
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the accuracy and performance of a new subcutaneous continuous glucose monitor (BD-CGM, Becton Dickinson) in hyperglycemic (high blood sugar) and hypoglycemic (low blood sugar) "clamp" conditions and during meal excursions over the course of 72 hours as compared to a commercially available monitor.
Conditions
- Diabetes
Interventions
BD CGM with Outer LayerDevice
continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
BD CGM without Outer LayerDevice
continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
Medtronic iPro2 Professional CGMDevice
continuous subcutaneous glucose monitoring for 72 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood GlucoseTime frame: 72 hours
- Number of participants with adverse eventsTime frame: up to 89 days or until the subject is discharged
Locations
1 site in 1 country. Site status is shown where the registry gives one.
>LMC Endocrinology Centre, Clinical Research Unit
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.